Exicure's Series C Round

Exicure raised a round of funding on June 17, 2014.

Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. The company's 3-dimensional, spherical nucleic acid (SNA) ar…

Articles about Exicure's Series C Round: